p53-Independent role of MDM2 in TGF-β1 resistance

Science

Volumn 282, Issue 5397, 1998, Pages 2270-2272

  Sun, Peiqing ^a   Dong, Ping ^a   Dai, Kang ^a,c   Hannon, Gregory J ^a   Beach, David ^b  

^a Simons Center for Quantitative Biology   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST TUMOR; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MUTATION; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION; GENES, P53; GENES, RETINOBLASTOMA; GENETIC VECTORS; HUMANS; MICE; MINK; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE; MUSTELA VISON;

EID: 0032545222     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5397.2270     Document Type: Article

References (35)

1. Y. Zhu, J. A. Richardson, L. F. Parada, J. M. Graff, Cell 94, 703 (1998).
2. J. Filmus and R. S. Kerbel, Curr. Opin. Oncol. 5, 123 (1993).
3. A. Kimchi, X. F. Wang, R. A. Weinberg, S. Cheifetz, J. Massagué, Science 240, 196 (1988).
4. K. Eppert et al., Cell 86, 543 (1996).
5. M. Schutte et al., Cancer Res. 56, 2527 (1996).
6. S. N. Wagner, C. Wagner, L. Briedigkeit, M. Goos, Br. J. Dermatol. 138, 13 (1998).
7. 7 cells were infected. The infected cells were selected with hygromycin and then subjected to TGF-β treatment for 3 months. Integrated proviruses were then excised with Cre recombinase from genomic DNA isolated from plates containing resistance cells. cDNA from 38 plates of resistant cells have been recovered and sequenced thus far. Among these, seven plates contained a cDNA encoding Mdm2, one contained c-myc, and seven contained NF-IX-1.
8. The cDNA expression vector (HygroMaRXII; P. Sun, G. J. Hannon, D. Beach, unpublished data) was designed based on Molony murine leukemia virus (MoMLV). We included a recognition site (loxP) for Cre recombinase in a 3′ long terminal repeat (LTR) and a bacterial replicon and a bacterial selectable marker within the retroviral genome. These modifications allow easy and efficient recovery of cDNAs by Cre-mediated excision of integrated proviruses from the genome. The recovered circular plasmids contained a single LTR, and thus could be directly used to produce recombinant viruses for further studies.
9. P. Sun, K. Dai, G. J. Hannon, D. Beach, data not shown.
10. M. C. Alexandrow, M. Kawabata, M. Aakre, H. L. Moses, Proc. Natl. Acad. Sci. U.S.A. 92, 3239 (1995).
11. S. Kulkarni and R. M. Gronostajski, Cell Growth Differ. 7, 501 (1996).
12. J. Momand and G. P. Zambetti, J. Cell. Biochem. 64, 343 (1997).
13. D. Michalovitz, O. Halevy, M. Oren. Cell 62, 671 (1990).
14. P. W. Hinds et al., Cell Growth Differ. 1, 571 (1990).
15. M. Hachiya et al., Anticancer Res. 14, 1853 (1994).
16. M. E. Ewen, C. J. Oliver, H. K. Sluss, S. J. Miller, D. S. Peeper, Genes Dev. 9, 204 (1995).
17. M. Laiho, J. A. DeCaprio, J. W. Ludlow, D. M. Livingston, J. Massagué, Cell 62, 175 (1990).
18. J. A. Pietenpol et al., ibid. 61, 777 (1990).
19. J. K. Schwarz et al., Proc. Natl. Acad. Sci. U.S.A. 92, 483 (1995).
20. S. N. Boyer, D. E. Wazer, V. Band, Cancer Res. 56, 4620 (1996).
21. Z. X. Xiao et al., Nature 375, 694 (1995).
22. K. Martin et al., ibid. 375, 691 (1995).
23. P. D. Adams and W. G. Kaelin Jr., Semin. Cancer Biol. 6, 99 (1995).
24. P. C. Nowell and J. S. Moore, Immunol. Res. 17, 171 (1998).
25. P. Schmid, P. Itin, T. Rufli, Carcinogenesis 16, 1499 (1995).
26. K. Krasagakis, C. Garbe, P. I. Schrier, C. E. Orfanos, Anticancer Res. 14, 2565 (1994).
27. M. Reiss and M. H. Barcellos-Hoff, Breast Cancer Res. Treat. 45, 81 (1997).
28. C. Poremba et al., Oncol. Res. 7, 331 (1995).
29. C. E. Bueso-Ramos et al., Breast Cancer Res. Treat. 37, 179 (1996).
30. M. Jiang et al., Int. J. Cancer 74, 529 (1997).
31. T. Gunther, R. Schneider-Stock, J. Rys, A. Niezabitowski, A. Roessner, J. Cancer Res. Clin. Oncol. 123, 388 (1997).
32. T. Watanabe, A. Ichikawa, H. Saito, T. Hotta, Leuk. Lymphoma 21, 391 (1996).
33. A. Teti et al., Int. J. Cancer 72, 1013 (1997).
34. I. Sigalas, A. H. Calvert, J. J. Anderson, D. E. Neal, J. Lunec, Nature Med. 2, 912 (1996).
35. We thank B. Vogelstein, D. Livingston, A. Levine, and M. Roussel for reagents; Berlex, Inc. for TGF-β; and R. Maestro and D. Conklin for helpful comments. Supported in part by grants from NIH (D.B. and G.J.H.), the Helen Hay Whitney Foundation (P.S.), the U.S. Army (C.J.H.), and the Pew Foundation (G.J.H.). D.B. is supported by the Hugh and Catherine Stevenson Fund.